News

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States

Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets).

Welcome everyone, I'm Frank Condella, the Chair of Mayne Pharma. It is a pleasure to welcome you to Mayne Pharma’s 2021 Annual General Meeting. As we have a quorum present, I am delighted to open the meeting

Today I will provide you with an update on the launch of NEXTSTELLIS our novel contraceptive which received FDA approval earlier this year together with some comments around our evolving specialty products business model and our outlook.

Mayne Pharma Group Limited (ASX: MYX) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application (ANDA) for a generic version of NUVARING.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Carolyn Myers, M.B.A., Ph.D. has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately